Loading...
Docoh

Oragenics (OGEN)

News

From Benzinga Pro
Oragenics Chair Sends Letter To Shareholders
17 May 22
News, Management
Oragenics, Inc. (NYSE:OGEN) (“Oragenics” or the “Company”) today issued the following letter to shareholders from its Executive Chairman, Frederick W. Telling, Ph.D.: To My Fellow
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
27 Apr 22
Biotech, Earnings, Large Cap, M&A, News, Penny Stocks, Health Care, Financing, Offerings, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Earnings Scheduled For April 27, 2022
27 Apr 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter.
Oragenics's Earnings: A Preview
26 Apr 22
Earnings
Oragenics (AMEX:OGEN) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Oragenics will report an earnings per share (EPS) of $-0.02.
Oragenics Extends Collaboration To Develop Vaccines Against Future Variants Of Coronaviruses
6 Apr 22
Biotech, General
Agreement extends current licensing and collaboration agreement to include rapid production of intranasal vaccine candidates against future variants TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE:OGEN)
68 Biggest Movers From Yesterday
5 Apr 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation.
Executives Buy Around $5.5M Of 3 Penny Stocks
4 Apr 22
Long Ideas, News, Penny Stocks, Small Cap, Insider Trades, Markets, Trading Ideas
US crude oil futures traded higher on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
4 Penny Stocks Insiders Are Buying
31 Mar 22
Long Ideas, News, Penny Stocks, Insider Trades, Markets, Trading Ideas
US crude oil futures traded sharply lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Oragenics Reports Received Audit Opinion Of Going Concern Explanation
25 Mar 22
News
Oragenics, Inc. (NYSE:OGEN) (“Oragenics” or the “Company”) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2021, which was filed on
Oragenics Initiates Pivotal IND-Enabling Toxicology Study On Its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
22 Mar 22
Biotech, News, FDA, General
Data to establish the safety profile and human dose of vaccine candidate Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today announced the initiation of a Good Laboratory Practice
Oragenics Partners With KBI Biopharma To Produce Material For Its Intranasal COVID-19 Vaccine Candidate
10 Mar 22
Biotech, News, Penny Stocks, Health Care, Contracts, General
Oragenics Enters Agreement With KBI Biopharma For Process Transfer, Optimization And cGMP Manufacturing Of Co.'s Intranasal Vaccine Candidate NT-CoV2-1; KBI To Produce Material For Use In Future Expected Phase 2 Clinical Trial Of Oragenics' Vaccine
10 Mar 22
Biotech, General
KBI to produce material for use in future expected Phase 2 clinical trial of Oragenics' intranasal vaccine candidate TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE:OGEN) (“Oragenics” or the
Oragenics Announces Posting Of Preprint Manuscript On Data For Intranasal SARS-CoV-2 Vaccine Candidate
3 Mar 22
Biotech, News, Penny Stocks, FDA, General
Intranasal Immunization Lowers the Viral Load Below the Limit of Detection in Lungs of Hamsters Oragenics, Inc. (NYSE: OGEN) ("Oragenics" or the "Company") today announced the posting of aIntranasal Immunization Lowers the Viral Load Below the Limit of Detection in Lungs of Hamsters

Press releases

From Benzinga Pro
Oragenics Issues Letter to Shareholders
17 May 22
Press Releases
Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today issued the following letter to shareholders from its Executive Chairman, Frederick W. Telling, Ph.D.: To My Fellow Shareholders, I am pleased to share
Oragenics to Participate at the World Vaccine Congress Washington 2022
18 Apr 22
Press Releases
Company to showcase NT-CoV2-1, a patient-friendly Covid vaccine candidate Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronavirus,
Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses
6 Apr 22
Press Releases
Agreement extends current licensing and collaboration agreement to include rapid production of intranasal vaccine candidates against future variants Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
25 Mar 22
Press Releases
Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2021, which was filed on March 24, 2022 with the
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
22 Mar 22
Press Releases
Data to establish the safety profile and human dose of vaccine candidate Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today announced the initiation of a Good Laboratory Practice (GLP) toxicology study to
Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1
10 Mar 22
Press Releases
KBI to produce material for use in future expected Phase 2 clinical trial of Oragenics' intranasal vaccine candidate Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today announced it has entered into an
Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript
3 Mar 22
Press Releases
Intranasal Immunization Lowers the Viral Load Below the Limit of Detection in Lungs of Hamsters Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") today announced the posting of a preprint manuscript in bioRxiv